博斯韦尔酸与低剂量的电离辐射协同作用,以减轻小鼠在乙胺诱导的肝脑病变
Dina E Saad1, Somaya Z Mansour1, Eman I Kandil2
1Radiation Biology Research, National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority, Cairo, Egypt.
BMC pharmacology & toxicology
|January 13, 2025
概括
这项研究表明,博斯韦利克酸 (BA) 与低剂量马辐射 (LDR) 结合,可以改善肝脏和大脑功能,在肝脏脑病变 (HE) 的动物模型中. 这种组合可能为HE提供一种新的治疗方法.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 神经科学是一个神经科学.
- 辐射生物学 辐射生物学
背景情况:
- 肝脑病变 (HE) 是一种复杂的神经综合征,由急性或慢性肝衰竭引起.
- 血氨水平升高和神经炎症是HE的关键病理特征.
- 目前对HE的治疗策略存在局限性,需要新的治疗方法.
研究的目的:
- 为了研究博斯韦尔酸 (BA) 和低剂量玛辐射 (LDR) 在乙 (TAA) 诱导的HE鼠模型中的潜在的肝保护和神经保护作用.
- 评估BA和LDR单独和组合对HE生物化学标记物,细胞因子水平和神经递质含量的影响.
主要方法:
- 大鼠每周两次服用TAA,持续四周,以诱导肝损伤和HE.
- 实验组每天接受BA治疗 (175 mg/kg) 和/或分成的LDR (0.25 Gy两次).
- 进行了生物化学测试 (肝酶,氨,细胞因子,偏氧酶-1) 以及肝脏和脑组织的组织病理学检查.
主要成果:
- TAA的使用显著增加了肝酶,血氨和促炎细胞因子 (IL6,IL12,IL18) 的含量,同时降低了偏氧酶-1活性和神经递质水平.
- 单独使用BA或与LDR结合治疗,在这些生化和神经学参数上显著改善.
- 组织病理学分析证实了生物化学发现,在治疗组中显示肝脏和脑组织损伤减少.
结论:
- 联合使用BA和LDR在老鼠中显示出对TAA诱导的HE具有有前途的肝保护和神经保护作用.
- 这种治疗组合有效地减轻了高氨血和相关的肝脏和大脑损伤.
- BA和LDR代表了一种潜在的新型治疗策略,用于治疗肝脏脑病变.
相关概念视频
Combined Effects of Drugs: Synergism
6.4K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
6.4K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
Drug Toxicity: Dose-Dependent Reactions
245
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
245
Drug toxicity: Drug–Drug Interaction
437
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
437
Hepatic Encephalopathy
71
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic...
71


